More evidence supports ventricular assist devices in complex angioplasty procedures

Original title: Percutaneous Left Ventricular Assist Device with Tandem Heart for High-Risk Percutaneous Coronary Intervention: The Mayo Clinic Experience. Reference: Oluseun O Alli, et al. Catheterization and Cardiovascular Intervention 80:728:734

There is a small group of poor surgical patients admitted for surgery that due to complex comorbidity, coronary anatomy and compromised left ventricular function that can be treated with coronary angioplasty (PCI) as an alternative. 

The goal of this study was to analyze the feasibility of Tandem Heart Cardiac Assist (Cardiac Assist, Pittsburgh, PA) ventricular assist devices in high risk patients. This is a retrospective analysis from a site that included 54 patients undergoing PCI with ventricular assistance.

High risk criteria were: <30% median ejection fraction, a threatening >8 cardiac score, vessel occlusion and the presence of comorbidities contraindicating cardiac surgery.

Two operators performed the procedures. The most relevant of baseline features were: average age 72, median ejection fraction 20%, diabetics 41%, previous revascularization surgery 50%, previous MI 52%, and counterpulsation balloon 45%.

30% presented cardiogenic shock, solved at procedure. Coronary anatomy was complex reaching a median Syntax score of 33. PCI was performed to the main left and multiple vessels in 62% and a total of 48% required rotablation.

The procedure had a 97% success rate. The use of ventricular assistance significantly improved L/min rates, mean auricular pressure, pulmonary pressure and Wedge pressure. Improvement was sustained after device removal. Survival rate at 30 days was 90%, and 87% at six months.

Conclusion 

Ventricular assistance is feasible as therapeutic strategy in patients with complex coronary disease, compromised ventricular function and high surgical risk..

Editorial Comment:

This study shows that high risk patients that make bad surgical candidates can be treated, but the adequate tools to achieve successful outcomes still need further development. The study is retrospective, it involved only one site, very few patients and only two operators; these factors constitute limitations that weaken external validation but serve as support for further extensive research.

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation – Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...